Back to Journals » International Journal of Nephrology and Renovascular Disease » Volume 9

Efficacy and safety of iron isomaltoside (Monofer®) in the management of patients with iron deficiency anemia

Authors Kalra P, Bhandari S

Received 16 November 2015

Accepted for publication 5 January 2016

Published 10 March 2016 Volume 2016:9 Pages 53—64

DOI https://doi.org/10.2147/IJNRD.S89704

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Madhusudan Venkatareddy

Peer reviewer comments 2

Editor who approved publication: Professor Pravin Singhal


Philip A Kalra,1 Sunil Bhandari2,3

1Department of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, UK; 2Hull and East Yorkshire Hospitals NHS Trust, Hull, UK; 3Hull York Medical School, Hull, UK

Abstract: New intravenous (IV) iron preparations should ideally be capable of delivering a wide dosing range to allow iron correction in a single or low number of visits, a rapid infusion (doses up to 1,000 mg must be administered over more than 15 minutes and doses exceeding 1,000 mg must be administered over 30 minutes or more), and minimal potential side effects including low catalytic/labile iron release with minimal risk of anaphylaxis. Furthermore, they should be convenient for the patient and health-care professional, and cost effective for the health-care system. The intention behind the development of iron isomaltoside (Monofer®) was to fulfill these requirements. Iron isomaltoside has been shown to be effective in treating iron deficiency anemia across multiple therapeutic patient groups and compared to placebo, IV iron sucrose, and oral iron. Iron isomaltoside consists of iron and a carbohydrate moiety where the iron is tightly bound in a matrix structure. It has a low immunogenic potential, a low potential to release labile iron, and does not appear to be associated with clinically significant hypophosphatemia. Due to the structure of iron isomaltoside, it can be administered in high doses with a maximum single dosage of 20 mg/kg body weight. Clinical trials and observational studies of iron isomaltoside show that it is an effective and well-tolerated treatment of anemia across different therapeutic areas with a favorable safety profile.

Keywords: iron deficiency anemia, iron isomaltoside, high dose, iron treatment, hypophosphatemia, intact fibroblast growth factor 23

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]